PortfoliosLab logo
ABSI vs. RXRX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ABSI and RXRX is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Performance

ABSI vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Absci Corporation (ABSI) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

-90.00%-85.00%-80.00%-75.00%-70.00%December2025FebruaryMarchAprilMay
-87.03%
-87.80%
ABSI
RXRX

Key characteristics

Sharpe Ratio

ABSI:

-0.44

RXRX:

-0.53

Sortino Ratio

ABSI:

-0.23

RXRX:

-0.46

Omega Ratio

ABSI:

0.97

RXRX:

0.95

Calmar Ratio

ABSI:

-0.50

RXRX:

-0.56

Martin Ratio

ABSI:

-1.39

RXRX:

-1.55

Ulcer Index

ABSI:

33.24%

RXRX:

32.81%

Daily Std Dev

ABSI:

98.25%

RXRX:

93.12%

Max Drawdown

ABSI:

-96.20%

RXRX:

-90.39%

Current Drawdown

ABSI:

-90.76%

RXRX:

-89.38%

Fundamentals

Market Cap

ABSI:

$365.50M

RXRX:

$2.32B

EPS

ABSI:

-$0.94

RXRX:

-$1.80

PS Ratio

ABSI:

80.61

RXRX:

39.37

PB Ratio

ABSI:

2.04

RXRX:

2.07

Total Revenue (TTM)

ABSI:

$3.64M

RXRX:

$59.76M

Gross Profit (TTM)

ABSI:

-$2.98M

RXRX:

-$46.00K

EBITDA (TTM)

ABSI:

-$70.71M

RXRX:

-$534.16M

Returns By Period

In the year-to-date period, ABSI achieves a 6.87% return, which is significantly higher than RXRX's -35.06% return.


ABSI

YTD

6.87%

1M

23.35%

6M

-30.52%

1Y

-43.32%

5Y*

N/A

10Y*

N/A

RXRX

YTD

-35.06%

1M

10.58%

6M

-36.65%

1Y

-48.89%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ABSI vs. RXRX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ABSI
The Risk-Adjusted Performance Rank of ABSI is 2424
Overall Rank
The Sharpe Ratio Rank of ABSI is 2727
Sharpe Ratio Rank
The Sortino Ratio Rank of ABSI is 3131
Sortino Ratio Rank
The Omega Ratio Rank of ABSI is 3131
Omega Ratio Rank
The Calmar Ratio Rank of ABSI is 2020
Calmar Ratio Rank
The Martin Ratio Rank of ABSI is 1111
Martin Ratio Rank

RXRX
The Risk-Adjusted Performance Rank of RXRX is 1919
Overall Rank
The Sharpe Ratio Rank of RXRX is 2323
Sharpe Ratio Rank
The Sortino Ratio Rank of RXRX is 2525
Sortino Ratio Rank
The Omega Ratio Rank of RXRX is 2727
Omega Ratio Rank
The Calmar Ratio Rank of RXRX is 1717
Calmar Ratio Rank
The Martin Ratio Rank of RXRX is 66
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ABSI vs. RXRX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Absci Corporation (ABSI) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current ABSI Sharpe Ratio is -0.44, which is comparable to the RXRX Sharpe Ratio of -0.53. The chart below compares the historical Sharpe Ratios of ABSI and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2025FebruaryMarchAprilMay
-0.44
-0.53
ABSI
RXRX

Dividends

ABSI vs. RXRX - Dividend Comparison

Neither ABSI nor RXRX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ABSI vs. RXRX - Drawdown Comparison

The maximum ABSI drawdown since its inception was -96.20%, which is greater than RXRX's maximum drawdown of -90.39%. Use the drawdown chart below to compare losses from any high point for ABSI and RXRX. For additional features, visit the drawdowns tool.


-90.00%-85.00%-80.00%-75.00%-70.00%December2025FebruaryMarchAprilMay
-90.76%
-87.80%
ABSI
RXRX

Volatility

ABSI vs. RXRX - Volatility Comparison

The current volatility for Absci Corporation (ABSI) is 28.84%, while Recursion Pharmaceuticals, Inc. (RXRX) has a volatility of 39.86%. This indicates that ABSI experiences smaller price fluctuations and is considered to be less risky than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%December2025FebruaryMarchAprilMay
28.84%
39.86%
ABSI
RXRX

Financials

ABSI vs. RXRX - Financials Comparison

This section allows you to compare key financial metrics between Absci Corporation and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M25.00M20212022202320242025
665.00K
14.75M
(ABSI) Total Revenue
(RXRX) Total Revenue
Values in USD except per share items